TY - JOUR
T1 - Surveillance and control of meningococcal disease in the COVID-19 era
T2 - A Global Meningococcal Initiative review
AU - Alderson, Mark R.
AU - Arkwright, Peter D.
AU - Bai, Xilian
AU - Black, Steve
AU - Borrow, Ray
AU - Caugant, Dominique A.
AU - Dinleyici, Ener Cagri
AU - Harrison, Lee H.
AU - Lucidarme, Jay
AU - McNamara, Lucy A.
AU - Meiring, Susan
AU - Sáfadi, Marco A.P.
AU - Shao, Zhujun
AU - Stephens, David S.
AU - Taha, Muhamed Kheir
AU - Vazquez, Julio
AU - Zhu, Bingqing
AU - collaborators, G. M.I.
N1 - Publisher Copyright:
© 2021
PY - 2022/3
Y1 - 2022/3
N2 - This review article incorporates information from the 4th Global Meningococcal Initiative summit meeting. Since the introduction of stringent COVID-19 infection control and lockdown measures globally in 2020, there has been an impact on IMD prevalence, surveillance, and vaccination compliance. Incidence rates and associated mortality fell across various regions during 2020. A reduction in vaccine uptake during 2020 remains a concern globally. In addition, several Neisseria meningitidis clonal complexes, particularly CC4821 and CC11, continue to exhibit resistance to antibiotics, with resistance to ciprofloxacin or beta-lactams mainly linked to modifications of gyrA or penA alleles, respectively. Beta-lactamase acquisition was also reported through horizontal gene transfer (blaROB-1) involving other bacterial species. Despite the challenges over the past year, progress has also been made on meningococcal vaccine development, with several pentavalent (serogroups ABCWY and ACWYX) vaccines currently being studied in late-stage clinical trial programmes.
AB - This review article incorporates information from the 4th Global Meningococcal Initiative summit meeting. Since the introduction of stringent COVID-19 infection control and lockdown measures globally in 2020, there has been an impact on IMD prevalence, surveillance, and vaccination compliance. Incidence rates and associated mortality fell across various regions during 2020. A reduction in vaccine uptake during 2020 remains a concern globally. In addition, several Neisseria meningitidis clonal complexes, particularly CC4821 and CC11, continue to exhibit resistance to antibiotics, with resistance to ciprofloxacin or beta-lactams mainly linked to modifications of gyrA or penA alleles, respectively. Beta-lactamase acquisition was also reported through horizontal gene transfer (blaROB-1) involving other bacterial species. Despite the challenges over the past year, progress has also been made on meningococcal vaccine development, with several pentavalent (serogroups ABCWY and ACWYX) vaccines currently being studied in late-stage clinical trial programmes.
KW - Antibiotic resistance
KW - COVID-19
KW - Coronavirus
KW - Invasive meningococcal disease
KW - Neisseria meningitidis
KW - Pandemic
KW - Serogroup
KW - Sexual transmission
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85120820550&partnerID=8YFLogxK
U2 - 10.1016/j.jinf.2021.11.016
DO - 10.1016/j.jinf.2021.11.016
M3 - Review article
AN - SCOPUS:85120820550
SN - 0163-4453
VL - 84
SP - 289
EP - 296
JO - Journal of Infection
JF - Journal of Infection
IS - 3
ER -
